Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00635570 · ClinicalTrials.gov registry record · Phase 4
Acceptability of the NuvaRing Among Students
A Phase 4 study of Birth Control Compliance, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 4
- Development phase
- 273
- Enrollment target
- 3
- Study locations
NCT00635570: Completed Phase 4 study of Birth Control Compliance, sponsored by University of Chicago.
NCT00635570 is a Phase 4 study of Birth Control Compliance that has completed, run by University of Chicago. The registered enrollment target is 273 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (47% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00635570, a Phase 4 study of Birth Control Compliance, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 273 participants
- Enrollment target
- 3
- Study locations
Study Summary
The ACCEPT study is a Phase IV trial in which women are randomized to either the NuvaRing® vaginal contraceptive ring or a low dose oral contraceptive to assess compliance, side effects, overall acceptability and intent to continue use of the method. The study is focused on the acceptability of the vaginal ring among female undergraduate or graduate students.
Primary Outcome
"Perfect use" was defined as reporting never missing a pill or never removing the contraceptive vaginal ring for more than 2 hours during days 1-21 of all three monthly cycles
Conditions Studied
Interventions
- DRUG Ortho Tri-cyclen Lo
- DEVICE NuvaRing
Study Locations (3)
Illinois
- University of Chicago, Section of Family Planning - Chicago
- University of Chicago - Chicago
- University of Illinois - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 273 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-07 |
| Phase | Phase 4 |
What the finished NCT00635570 record still lists
NCT00635570 is an interventional study that assigns participants to a tested intervention. The registered 273 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (47% lower).
The record links to 1 condition, with Birth Control Compliance appearing as the primary indexed condition, and to 2 interventions - of which Ortho Tri-cyclen Lo is the first listed.
NCT00635570 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00635570 about?
NCT00635570 is a clinical study titled "Acceptability of the NuvaRing Among Students". The ACCEPT study is a Phase IV trial in which women are randomized to either the NuvaRing® vaginal contraceptive ring or a low dose oral contraceptive to assess compliance, side effects, overall acceptability and intent to continue use of the method. The study is focused on the acceptability of the ...
What is the current status of trial NCT00635570?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 273 participants. The study started on 2008-07. Estimated completion is 2009-07.
What conditions does trial NCT00635570 study?
This clinical trial studies the following conditions: Birth Control Compliance.
What interventions are being tested in trial NCT00635570?
The interventions under investigation include: Ortho Tri-cyclen Lo (DRUG), NuvaRing (DEVICE).
Who is sponsoring clinical trial NCT00635570?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00635570 being conducted?
This trial has 3 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00635570's enrollment target sits among peer trials
273 315th of 2000 higher than 1,686 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07229430 · 273 participants · NA
Safety and Effectiveness Evaluation of the High-intensity Focused Ultrasound Device for Lifting Lax Submental and Neck Tissue
- NCT03808922 · 274 participants · Phase 3
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
- NCT04573504 · 274 participants · Phase 4
Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair
- NCT05289557 · 274 participants · Phase 3
The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia